European equities traded in the US as American depositary receipts were higher late Friday morning, rising 1.55% to 1,293.05 on the S&P Europe Select ADR Index. The index is up more than 5% for the week.
From continental Europe, the gainers were led by biopharmaceutical companies Cellectis (CLLS) and argenx (ARGX), which advanced 14% and 5.6% respectively. They were followed by pharmaceutical company Novo Nordisk (NVO) and biopharmaceutical company Genfit (GNFT), which increased 4.6% and 2.5% respectively.
The decliners from continental Europe were led by biopharmaceutical company DBV Technologies (DBVT) and internet advertising firm Criteo (CRTO), which fell 4.3% and 4% respectively. They were followed by furniture manufacturer Natuzzi (NTZ), which dropped 3.5%.
From the UK and Ireland, the gainers were led by biopharmaceutical companies Biodexa Pharmaceuticals (BDRX) and Amarin (AMRN), which climbed 8.3% and 6.4% respectively. They were followed by pharmaceutical company Silence Therapeutics (SLN) and biopharmaceutical company NuCana (NCNA), which rose 3.8% and 2.7% respectively.
The decliners from the UK and Ireland were led by biotech firm Trinity Biotech (TRIB) and biopharmaceutical company Adaptimmune Therapeutics (ADAP), which lost 7% and 2.3% respectively. They were followed by software firm Endava (DAVA) and cruise line operator Carnival (CUK), which were down 2.1% each.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。